Drug Trial Radar · NCT07823348
JS207 Plus JS007 Versus Toripalimab Plus Bevacizumab as First-Line Treatment for Advanced Liver Cancer
Last checked: Nov 19, 2026Latest source record: Sep 16, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Not yet recruiting
Enrollment
560
Planned (sponsor's estimate)
Start
Oct 8, 2026
Primary completion
Oct 30, 2029
Study completion Oct 30, 2031
Sponsor
- Lead sponsor
- Shanghai Junshi Bioscience Co., Ltd.Academic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Sep 16, 2026
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Prevention
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a multicenter, randomized, open-label, controlled Phase III clinical study designed to evaluate the efficacy and safety of JS207 in combination with JS007 versus toripalimab in combination with bevacizumab as first-line treatment in participants with advanced HCC. All study participants have unresectable locally advanced, recurrent, or metastatic HCC and have not previously received systemic anti-tumor therapy for advanced disease. Approximately 560 participants are planned to be enrolled in this study. The JS207 + JS007 group (experimental group) and the toripalimab + bevacizumab group (positive control group) are each planned to enroll 280 participants.
Conditions
- Hepatocellular Carcinoma
Interventions
JS207Drug
PD-1/VEGF bispecific antibody supplied as a lyophilized powder for intravenous infusion.
JS007Drug
CTLA-4 monoclonal antibody supplied as an injectable solution for intravenous infusion.
ToripalimabDrug
PD-1 monoclonal antibody supplied as an injectable solution for intravenous infusion.
BevacizumabDrug
VEGF monoclonal antibody supplied as an injectable solution for intravenous infusion.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Progression-Free Survival Assessed by Blinded Independent Central Review (BICR-PFS)Time frame: From randomization to disease progression or death, whichever occurs first; assessed up to 24 months.
- Overall Survival (OS)Time frame: From randomization to death from any cause; assessed up to 66 months.
Locations
2 sites in 1 country. Site status is shown where the registry gives one.
Harbin Medical University Cancer Hospital
Harbin, Heilongjiang, China
Zhongshan Hospital, Fudan University
Shanghai, Shanghai Municipality, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.